Jarith L Ebenau1, Denise Visser2, Sander C J Verfaillie2, Tessa Timmers2, Mardou S S A van Leeuwenstijn3, Mara Ten Kate2, Albert D Windhorst2, Frederik Barkhof2,4, Philip Scheltens3, Niels D Prins3,5, Ronald Boellaard2, Wiesje M van der Flier3,6, Bart N M van Berckel2. 1. Alzheimer Centre, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands. j.ebenau@amsterdamumc.nl. 2. Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands. 3. Alzheimer Centre, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands. 4. UCL Institutes of Neurology and Healthcare Engineering, London, UK. 5. Brain Research Centre, Amsterdam, The Netherlands. 6. Department of Epidemiology & Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
Abstract
PURPOSE: The role of cerebral blood flow (CBF) in the early stages of Alzheimer's disease is complex and largely unknown. We investigated cross-sectional and longitudinal associations between CBF, amyloid burden, and cognition, in cognitively normal individuals with subjective cognitive decline (SCD). METHODS: We included 187 cognitively normal individuals with SCD from the SCIENCe project (65 ± 8 years, 39% F, MMSE 29 ± 1). Each underwent a dynamic (0-70 min) [18F]florbetapir PET and T1-weighted MRI scan, enabling calculation of mean binding potential (BPND; specific amyloid binding) and R1 (measure of relative (r)CBF). Eighty-three individuals underwent a second [18F]florbetapir PET (2.6 ± 0.7 years). Participants annually underwent neuropsychological assessment (follow-up time 3.8 ± 3.1 years; number of observations n = 774). RESULTS: A low baseline R1 was associated with steeper decline on tests addressing memory, attention, and global cognition (range betas 0.01 to 0.27, p < 0.05). High BPND was associated with steeper decline on tests covering all domains (range betas - 0.004 to - 0.70, p < 0.05). When both predictors were simultaneously added to the model, associations remained essentially unchanged. Additionally, we found longitudinal associations between R1 and BPND. High baseline BPND predicted decline over time in R1 (all regions, range betasBP×time - 0.09 to - 0.14, p < 0.05). Vice versa, low baseline R1 predicted increase in BPND in frontal, temporal, and composite ROIs over time (range betasR1×time - 0.03 to - 0.08, p < 0.05). CONCLUSION: Our results suggest that amyloid accumulation and decrease in rCBF are two parallel disease processes without a fixed order, both providing unique predictive information for cognitive decline and each process enhancing the other longitudinally.
PURPOSE: The role of cerebral blood flow (CBF) in the early stages of Alzheimer's disease is complex and largely unknown. We investigated cross-sectional and longitudinal associations between CBF, amyloid burden, and cognition, in cognitively normal individuals with subjective cognitive decline (SCD). METHODS: We included 187 cognitively normal individuals with SCD from the SCIENCe project (65 ± 8 years, 39% F, MMSE 29 ± 1). Each underwent a dynamic (0-70 min) [18F]florbetapir PET and T1-weighted MRI scan, enabling calculation of mean binding potential (BPND; specific amyloid binding) and R1 (measure of relative (r)CBF). Eighty-three individuals underwent a second [18F]florbetapir PET (2.6 ± 0.7 years). Participants annually underwent neuropsychological assessment (follow-up time 3.8 ± 3.1 years; number of observations n = 774). RESULTS: A low baseline R1 was associated with steeper decline on tests addressing memory, attention, and global cognition (range betas 0.01 to 0.27, p < 0.05). High BPND was associated with steeper decline on tests covering all domains (range betas - 0.004 to - 0.70, p < 0.05). When both predictors were simultaneously added to the model, associations remained essentially unchanged. Additionally, we found longitudinal associations between R1 and BPND. High baseline BPND predicted decline over time in R1 (all regions, range betasBP×time - 0.09 to - 0.14, p < 0.05). Vice versa, low baseline R1 predicted increase in BPND in frontal, temporal, and composite ROIs over time (range betasR1×time - 0.03 to - 0.08, p < 0.05). CONCLUSION: Our results suggest that amyloid accumulation and decrease in rCBF are two parallel disease processes without a fixed order, both providing unique predictive information for cognitive decline and each process enhancing the other longitudinally.
Authors: Wenna Duan; Parshant Sehrawat; Arvind Balachandrasekaran; Ashish B Bhumkar; Paresh B Boraste; James T Becker; Lewis H Kuller; Oscar L Lopez; H Michael Gach; Weiying Dai Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Anton F Gietl; Geoffrey Warnock; Florian Riese; Andrea M Kälin; Antje Saake; Esmeralda Gruber; Sandra E Leh; Paul G Unschuld; Felix P Kuhn; Cyrill Burger; Linjing Mu; Burkhardt Seifert; Roger M Nitsch; Roger Schibli; Simon M Ametamey; Alfred Buck; Christoph Hock Journal: Neurobiol Aging Date: 2015-01-07 Impact factor: 4.673
Authors: Amir Fazlollahi; Fernando Calamante; Xiaoyun Liang; Pierrick Bourgeat; Parnesh Raniga; Vincent Dore; Jurgen Fripp; David Ames; Colin L Masters; Christopher C Rowe; Alan Connelly; Victor L Villemagne; Olivier Salvado Journal: J Magn Reson Imaging Date: 2019-05-30 Impact factor: 4.813
Authors: Willemijn J Jansen; Rik Ossenkoppele; Dirk L Knol; Betty M Tijms; Philip Scheltens; Frans R J Verhey; Pieter Jelle Visser; Pauline Aalten; Dag Aarsland; Daniel Alcolea; Myriam Alexander; Ina S Almdahl; Steven E Arnold; Inês Baldeiras; Henryk Barthel; Bart N M van Berckel; Kristen Bibeau; Kaj Blennow; David J Brooks; Mark A van Buchem; Vincent Camus; Enrica Cavedo; Kewei Chen; Gael Chetelat; Ann D Cohen; Alexander Drzezga; Sebastiaan Engelborghs; Anne M Fagan; Tormod Fladby; Adam S Fleisher; Wiesje M van der Flier; Lisa Ford; Stefan Förster; Juan Fortea; Nadia Foskett; Kristian S Frederiksen; Yvonne Freund-Levi; Giovanni B Frisoni; Lutz Froelich; Tomasz Gabryelewicz; Kiran Dip Gill; Olymbia Gkatzima; Estrella Gómez-Tortosa; Mark Forrest Gordon; Timo Grimmer; Harald Hampel; Lucrezia Hausner; Sabine Hellwig; Sanna-Kaisa Herukka; Helmut Hildebrandt; Lianna Ishihara; Adrian Ivanoiu; William J Jagust; Peter Johannsen; Ramesh Kandimalla; Elisabeth Kapaki; Aleksandra Klimkowicz-Mrowiec; William E Klunk; Sebastian Köhler; Norman Koglin; Johannes Kornhuber; Milica G Kramberger; Koen Van Laere; Susan M Landau; Dong Young Lee; Mony de Leon; Viviana Lisetti; Alberto Lleó; Karine Madsen; Wolfgang Maier; Jan Marcusson; Niklas Mattsson; Alexandre de Mendonça; Olga Meulenbroek; Philipp T Meyer; Mark A Mintun; Vincent Mok; José Luis Molinuevo; Hanne M Møllergård; John C Morris; Barbara Mroczko; Stefan Van der Mussele; Duk L Na; Andrew Newberg; Agneta Nordberg; Arto Nordlund; Gerald P Novak; George P Paraskevas; Lucilla Parnetti; Gayan Perera; Oliver Peters; Julius Popp; Sudesh Prabhakar; Gil D Rabinovici; Inez H G B Ramakers; Lorena Rami; Catarina Resende de Oliveira; Juha O Rinne; Karen M Rodrigue; Eloy Rodríguez-Rodríguez; Catherine M Roe; Uros Rot; Christopher C Rowe; Eckart Rüther; Osama Sabri; Páscual Sanchez-Juan; Isabel Santana; Marie Sarazin; Johannes Schröder; Christin Schütte; Sang W Seo; Femke Soetewey; Hilkka Soininen; Luiza Spiru; Hanne Struyfs; Charlotte E Teunissen; Magda Tsolaki; Rik Vandenberghe; Marcel M Verbeek; Victor L Villemagne; Stephanie J B Vos; Linda J C van Waalwijk van Doorn; Gunhild Waldemar; Anders Wallin; Åsa K Wallin; Jens Wiltfang; David A Wolk; Marzena Zboch; Henrik Zetterberg Journal: JAMA Date: 2015-05-19 Impact factor: 56.272
Authors: Y Chen; D A Wolk; J S Reddin; M Korczykowski; P M Martinez; E S Musiek; A B Newberg; P Julin; S E Arnold; J H Greenberg; J A Detre Journal: Neurology Date: 2011-11-16 Impact factor: 9.910
Authors: Reyes García de Eulate; Irene Goñi; Alvaro Galiano; Marta Vidorreta; Miriam Recio; Mario Riverol; José L Zubieta; María A Fernández-Seara Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Katherine J Bangen; Alexandra L Clark; Emily C Edmonds; Nicole D Evangelista; Madeleine L Werhane; Kelsey R Thomas; Lyzette E Locano; My Tran; Zvinka Z Zlatar; Daniel A Nation; Mark W Bondi; Lisa Delano-Wood Journal: Front Aging Neurosci Date: 2017-06-08 Impact factor: 5.750
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566